<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03967834</url>
  </required_header>
  <id_info>
    <org_study_id>19 SARC 04</org_study_id>
    <nct_id>NCT03967834</nct_id>
  </id_info>
  <brief_title>Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group</brief_title>
  <acronym>MIRAS</acronym>
  <official_title>Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a translational, open-label, multi-sites, prospective and retrospective cohort&#xD;
      study of 500 patients aimed at clinical and biological characterization of sarcoma of rare&#xD;
      subtype.&#xD;
&#xD;
      400 patients will be included in this prospective cohort study; they will be identified in&#xD;
      the investigating centers in the context of either routine care or a clinical study protocol.&#xD;
&#xD;
      Retrospective cases of patients (100 cases in total) will be identified in all centers&#xD;
      through the GSF/GETO clinical databases already setted up (including the clinical base&#xD;
      Conticabase).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metastasis-free survival for patients with localized disease.</measure>
    <time_frame>60 months for each patients</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival for patients with metastatic disease.</measure>
    <time_frame>60 months for each patients</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cancer-Testis Antigens (CTA) expression.</measure>
    <time_frame>60 months for each patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of patients presenting high-risk CINSARC (Complexity Index in SARComas) signature.</measure>
    <time_frame>60 months for each patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival.</measure>
    <time_frame>60 months for each patients</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Clear Cell Sarcoma</condition>
  <condition>Epithelioid Sarcoma</condition>
  <condition>Perivascular Epithelioid Cell Neoplasms</condition>
  <condition>Desmoplastic Small Round Cell Tumor</condition>
  <condition>Malignant Solitary Fibrous Tumors</condition>
  <condition>Alveolar Soft Part Sarcoma</condition>
  <condition>Epithelioid Hemangioendothelioma</condition>
  <condition>Low Grade Fibromyxoid Sarcoma</condition>
  <condition>Sclerosing Epithelioid Fibrosarcoma</condition>
  <arm_group>
    <arm_group_label>Patient with Soft Tissue Sarcoma (Prospective cohort)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient with Soft Tissue Sarcoma</intervention_name>
    <description>Tumor specimens will be collected for the study at diagnosis.&#xD;
A blood sample will be collected in all included patients at baseline, after the completion of the treatment (for patients included with a localized disease) or at the time of the first tumoral evaluation (for patients included with a metastatic disease), and at the time of progression.&#xD;
Patient's data (clinical, biological and disease data) will also be collected at baseline visit and then at each time point planned in the center for clinical benefit assessment (i.e. every 2 or 3 months) until progression or for a maximum duration of 5 years.</description>
    <arm_group_label>Patient with Soft Tissue Sarcoma (Prospective cohort)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years at the time of study entry.&#xD;
&#xD;
          2. Diagnosis of one of the following rare sarcoma subtype, confirmed by RRePS network:&#xD;
&#xD;
               -  Clear Cell Sarcoma (CCS)&#xD;
&#xD;
               -  Epithelioid Sarcoma (ES)&#xD;
&#xD;
               -  Perivascular Epithelioid Cell neoplasm (PEComa)&#xD;
&#xD;
               -  Desmoplastic Small Round Cell Tumours (DSRCT)&#xD;
&#xD;
               -  Malignant Solitary Fibrous Tumours (mSFT)&#xD;
&#xD;
               -  Alveolar Soft Part Sarcoma (ASPS)&#xD;
&#xD;
               -  Epithelioid Hemangioendothelioma (EH)&#xD;
&#xD;
               -  Low-Grade Fibromyxoid Sarcoma (LGFS)&#xD;
&#xD;
               -  Sclerosing Epithelioid Fibrosarcoma (SEF).&#xD;
&#xD;
          3. Localized/locally advanced or metastatic disease.&#xD;
&#xD;
          4. In case of localized disease, treatment must not have been yet initiated before&#xD;
             inclusion (except surgical excision).&#xD;
&#xD;
          5. In case of metastatic disease, project of new line of systemic treatment must have&#xD;
             been decided before inclusion.&#xD;
&#xD;
          6. Patient followed in the center within a standard of care procedure or clinical trial.&#xD;
&#xD;
          7. Archived tumor specimen at initial diagnosis available (before treatment initiation).&#xD;
&#xD;
          8. Evaluable disease (measurable as per RECIST 1.1) or not.&#xD;
&#xD;
          9. ECOG Performance status 0-3.&#xD;
&#xD;
         10. Patient able to participate and willing to give informed consent prior to performance&#xD;
             of any study-related procedures.&#xD;
&#xD;
         11. Patient affiliated to a Social Health Insurance in France.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of all other histotypes of soft tissue sarcoma.&#xD;
&#xD;
          2. Any condition contraindicated with procedures required by the protocol.&#xD;
&#xD;
          3. Known history of positive test for hepatitis B virus or hepatitis C virus or human&#xD;
             immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).&#xD;
&#xD;
          4. Any psychological, familial, geographic or social situation, according to the judgment&#xD;
             of investigator, potentially preventing the provision of informed consent or&#xD;
             compliance to study procedure.&#xD;
&#xD;
          5. Pregnant or breast-feeding woman.&#xD;
&#xD;
          6. Patient who has forfeited his/her freedom by administrative or legal award or who is&#xD;
             under guardianship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thibaud VALENTIN</last_name>
    <phone>+33 (0)5 31 15 51 70</phone>
    <email>Valentin.Thibaud@iuct-oncopole.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frédéric CHIBON</last_name>
    <phone>+33 (0)5 82 74 17 65</phone>
    <email>frederic.chibon@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Besancon - Site Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume MEYNARD</last_name>
      <phone>03 70 63 24 03</phone>
      <email>gmeynard@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale DUBRAY-LONGERAS</last_name>
      <phone>04 73 27 81 41</phone>
      <email>pascale.dubray-longeras@clermont.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas PENEL</last_name>
      <phone>03 20 29 59 59</phone>
      <email>n-penel@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armelle DUFRESNE</last_name>
      <phone>04 69 85 61 47</phone>
      <email>armelle.dufresne@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François BERTUCCI</last_name>
      <phone>04 91 22 35 37</phone>
      <email>bertuccif@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esma SAADA-BOUZID</last_name>
      <phone>04 92 03 15 14</phone>
      <email>esma.saada-bouzid@nice.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest - Site Rene Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle BOMPAS</last_name>
      <phone>02 40 67 99 39</phone>
      <email>emmanuelle.bompas@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thibaud VALENTIN</last_name>
      <phone>+33 (0)5 31 15 51 70</phone>
      <email>Valentin.Thibaud@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria RIOS</last_name>
      <phone>03 83 59 84 61</phone>
      <email>m.rios@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier MIR</last_name>
      <phone>01 42 11 61 35</phone>
      <email>olivier.mir@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Soft Tissue Sarcoma</keyword>
  <keyword>Clear Cell Sarcoma</keyword>
  <keyword>Epithelioid Sarcoma</keyword>
  <keyword>Perivascular Epithelioid Cell Neoplasms</keyword>
  <keyword>Desmoplastic Small Round Cell Tumor</keyword>
  <keyword>Malignant Solitary Fibrous Tumors</keyword>
  <keyword>Alveolar Soft Part Sarcoma</keyword>
  <keyword>Epithelioid Hemangioendothelioma</keyword>
  <keyword>Low Grade Fibromyxoid Sarcoma</keyword>
  <keyword>Sclerosing Epithelioid Fibrosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
    <mesh_term>Fibrosarcoma</mesh_term>
    <mesh_term>Sarcoma, Alveolar Soft Part</mesh_term>
    <mesh_term>Sarcoma, Clear Cell</mesh_term>
    <mesh_term>Hemangioendothelioma</mesh_term>
    <mesh_term>Solitary Fibrous Tumors</mesh_term>
    <mesh_term>Neoplasms, Fibrous Tissue</mesh_term>
    <mesh_term>Hemangioendothelioma, Epithelioid</mesh_term>
    <mesh_term>Perivascular Epithelioid Cell Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

